Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

287 articles about Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

• Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/1/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 22 nd Annual Global Investment Conference to be held virtually on September 14th-16th. Anthony DiTonno, Chief Executive Officer, is schedule

• Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

  8/31/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF have been accepted for presentation as a Late-Breaking Clinical Trial at this year’s Heart Failure Society of America (HFSA) Annual Scientific Meeting

• Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

  8/17/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update. “The recently completed Phase 2 trial of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) has garnered s

• Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

  7/20/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the expansion of its Board of Directors with the appointment of Steven Boyd and Keith Maher, M.D. Both Directors are from Armistice Capital, LLC, which recently purchased the Com

• Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

  7/6/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 2,523,611

• Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - June 03, 2020

  6/3/2020

  Tenax Therapeutics, Inc. announced that it received notice from The Nasdaq Stock Market, LLC on June 2, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

•  Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  6/2/2020

  Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)   - Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures - Demonstrated a significant improvement with 6-minute walk distance - No significant safety issues. - Management to host conference call and webcast today at

• Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

  4/9/2020

  Tenax Therapeutics, Inc. today announced that the last patient has completed their final visit in the Company’s Phase 2 clinical trial of levosimendan in patient

• Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial

  3/12/2020

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has completed enrollment of their Phase 2 clinical trial of levosimendan.

• Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

  3/12/2020

  Tenax Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 750,000 shares of its co

• Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

  2/21/2020

  Feb. 21, 2020 13:30 UTC MORRISVILLE, N.C.--( BUSINESS WIRE )-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic has joined our scientific advisory board. Tenax CEO

• Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

  10/31/2019

  Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, provided an update on its on-going clinical trial of levosimendan.

• Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference

  8/29/2019

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that management is scheduled to present and conduct one-on-one meetings at the H.C. Wainwright 21st Annual Global Investment Conference to be held in New York, NY on September 8th-10th.

• Tenax Therapeutics Provides Clinical Development Update

  8/23/2019

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan

• Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference

  2/4/2019

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with high unmet medical need, today announced that management is scheduled to present and conduct one-on-one meetings at the 2019 BIO CEO & Investor Conference to be held in New York, NY on February 11th and 12th

• Tenax Therapeutics to Present at Biotech Showcase Investor Conference

  1/4/2019

  Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with high unmet medical need, today announced that the Company will participate in Biotech Showcase Investor Conference in San Francisco, which takes place January 7-9, 2019

• Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

  12/11/2018

  Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the closing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax.

• Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

  12/7/2018

  Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the pricing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax.

• Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

  11/19/2018

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan

• Tenax Therapeutics to Present at Upcoming Investor Conferences

  9/20/2018

  Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market.